Zapping away AFib: first human test of new ablation device begins
NCT ID NCT06452589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device called the FieldForce Ablation System in 35 people with atrial fibrillation (AFib). The device uses short electrical pulses to destroy tiny areas of heart tissue causing the irregular rhythm. The main goals are to see if it is safe and if it can successfully isolate the pulmonary veins, a key step in treating AFib.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FieldForce Ablation System (pulsed field ablation device)
- What this could lead to
- If successful, this could provide a new, safer option for treating atrial fibrillation by using targeted electrical pulses to correct heart rhythm.
- What could go wrong
- This is a very early, first-in-human trial with only 35 people. The device may not work as expected or could cause side effects like heart rhythm problems or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL ARRHYTHMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Na Homolce Hospital
Prague, 150 00, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.